Study details
Enrolling now
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
AbbVie
NCT IDNCT06602479ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
408
Study length
about 2.6 years
Ages
18–70
Locations
16 sites in AL, CA, FL +7
About this study
This trial is testing a treatment called MEDI0618 compared to a placebo (inactive pill) in adults with episodic migraine. The goal is to see if MEDI0618 is safe and effective for treating this condition.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take MEDI0618
- 2.Take Placebo
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Neurology